A retrospective study assessing safety and efficacy issues with SARS-CoV-2 vaccines in Hodgkin Lymphoma patients receiving PD-1 Inhibitors
Latest Information Update: 01 Feb 2022
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 01 Feb 2022 New trial record
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition